This data adds to the primary analysis of the JUPITER study which demonstrated that CRESTOR (R) (rosuvastatin calcium) 20mg significantly reduced the risk of stroke by nearly half (48%; p=0.002), ...

Can u get crestor 20mg tablets usps This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Please note Crestor is also available in ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced results of the LUNAR (Limiting UNdertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin) study, which showed ...

Current international and national guidelines[2,3,4] continue to stress the significance of reducing LDL-cholesterol (LDL-C), an important risk factor for the development and progression of ...

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men ...

Crestor logo image Crestor (rosuvastatin calcium; AstraZeneca) tablets have been approved for use in pediatric patients aged 7-17 years with homozygous familial hypercholesterolemia (HoFH) to reduce ...

The FDA has approved Crestor (rosuvastatin calcium tablets, from AstraZeneca) to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in individuals without ...

Kyoto, Japan, Monday 29 September 2003. New data presented at the XIIIth International Symposium on Atherosclerosis (ISA) show AstraZeneca's highly effective statin CRESTOR (rosuvastatin) achieves ...

The results of a clinical trial involving nearly 2,000 patients suggest that AstraZeneca’s Crestor is more effective in getting patients with high cholesterol to their treatment goals than two ...

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego ...

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with ...